Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Spelman

Showing results (181-190 of 266) with videos related to

Pageof 27
Sort By:
Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews|February 3, 2023
The Impact of Sex on the Outcomes of Prosthetic Joint Infection Treatment with Debridement, Antibiotics and Implant Retention: A Systematic Review and Individual Patient Data Meta-analysisAnnabelle L Choong, Cade Shadbolt, Emma Choong, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 25, 2021
A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, AustraliaBrendan L Harney, Bradley Whitton, Emma Paige, et al.
The Lancet. HIV|April 13, 2018
The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trialThomas A Rasmussen, James H McMahon, J Judy Chang, et al.
The International Journal on Drug Policy|June 28, 2015
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis CMaryam Alavi, Tim Spelman, Gail V Matthews, et al.
Pharmacoeconomics|March 13, 2026
Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing ArthroplastyAn Tran-Duy, Sarah Asbury, Tim Spelman, et al.
BMJ Open|July 30, 2021
Treatment of tungiasis using a tea tree oil-based gel formulation: protocol for a randomised controlled proof-of-principle trialSolomon Abrha, Julia K Christenson, John McEwen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2025
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV CoinfectionJennifer Audsley, Anchalee Avihingsanon, Xin Li, et al.
AIDS (London, England)|March 17, 2017
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapyTalia M Mota, Thomas A Rasmussen, Ajantha Rhodes, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Pageof 27

Showing results (181-190 of 266) with videos related to

Sort By:
Pageof 27
Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews|February 3, 2023
The Impact of Sex on the Outcomes of Prosthetic Joint Infection Treatment with Debridement, Antibiotics and Implant Retention: A Systematic Review and Individual Patient Data Meta-analysisAnnabelle L Choong, Cade Shadbolt, Emma Choong, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 25, 2021
A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, AustraliaBrendan L Harney, Bradley Whitton, Emma Paige, et al.
The Lancet. HIV|April 13, 2018
The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trialThomas A Rasmussen, James H McMahon, J Judy Chang, et al.
The International Journal on Drug Policy|June 28, 2015
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis CMaryam Alavi, Tim Spelman, Gail V Matthews, et al.
Pharmacoeconomics|March 13, 2026
Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing ArthroplastyAn Tran-Duy, Sarah Asbury, Tim Spelman, et al.
BMJ Open|July 30, 2021
Treatment of tungiasis using a tea tree oil-based gel formulation: protocol for a randomised controlled proof-of-principle trialSolomon Abrha, Julia K Christenson, John McEwen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2025
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV CoinfectionJennifer Audsley, Anchalee Avihingsanon, Xin Li, et al.
AIDS (London, England)|March 17, 2017
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapyTalia M Mota, Thomas A Rasmussen, Ajantha Rhodes, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Pageof 27